|Awarded On||November 19, 2015|
|Title||Novel tumorigenic mechanisms of the LKB1 tumor suppressor in endometrial and cervical cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Diego H Castrillon|
|Cancer Sites||Cervix Uteri|
Genetic inactivation of the LKB1 tumor suppressor is a common, signature molecular lesion that occurs across many different types of common and incurable malignancies including lung cancer, uterine cancer, skin cancer, and pancreatic cancer. This program project seeks to understand the diverse biological actions of LKB1 and how these actions synergize in driving tumor initiation and spread in different types of cancers of the uterus. The goal is to gain a sufficient understanding of LKB1 biology to inform the development and implementation of effective therapeutic combinations that will specifically target tumors characterized by LKB1 loss.